Faranak Farzan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Faranak Farzan has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Paul Bernard Fitzgerald
School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia
27 shared publications - Mera S. Barr
Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
21 shared publications Zafiris J. Daskalakis
Department of Psychiatry, University of California San Diego
21 shared publicationsPrabhjot Dhami
Centre for Engineering-Led Brain Research, Simon Fraser University, 250-13450 102 Avenue, Surrey, British Columbia, V3T 0A3, Canada
15 shared publicationsSravya Atluri
Centre for Addiction and Mental Health
12 shared publications- Zafiris J. Daskalakis
Department of Psychiatry, University of Toronto, 250 College Street, Floor 8, Toronto, Ontario, Canada M5T 1R8
11 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by IOP Publishing in Journal of Neural Engineering
- Vol. 23 (2) , 026006
Insight into the impact of focal stimulation on large-scale network dynamics
Objective. Intrinsic functional brain activity forms a hierarchy, with local neural circuits integrated into large-scale networks. Determining how perturbations to a single brain region can rapidly propagate through this hierarchy and reconfigure global brain state dynamics is essential for decoding neural communication and advancing neuromodulation paradigms. Most prior studies have used perturbations to study trial-averaged responses, which miss moment-to-moment fluctuations, or focused on inter-regional connectivity, which characterizes brain activity as pairwise relationships rather than global states. How focal stimulation reshapes dynamics of global brain states remains unclear. Approach. We bridged this gap by combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) with microstate analysis, which captures global brain state dynamics with millisecond resolution. In 36 healthy participants, we examined how single-pulse TMS to the dorsolateral prefrontal cortex (DLPFC) and primary motor cortex (M1) reshapes the dynamics of the canonical EEG microstates (A–E) post-pulse. As key nodes of frontoparietal and primary motor networks, respectively, these targets let us investigate how stimulation of functionally distinct regions may differentially induce changes in global brain state dynamics. Analyses were conducted across repeated sessions within participants and validated in an independent dataset to ensure robustness and generalizability. Main results. Compared to pre-pulse baseline, DLPFC stimulation increased the occurrence and transitions of microstates D and E while suppressing those of A and B. These effects replicated across sessions and were validated in an independent dataset. Conversely, M1 stimulation increased microstate A occurrence post-pulse while reducing the occurrence of B. Furthermore, post-pulse microstate dynamics differed significantly from baseline after DLPFC stimulation compared to M1. Significance. These findings demonstrate that focal stimulation induces region-specific effects on global brain state dynamics, providing a mechanistic foundation for neuromodulation strategies to harness site-specific effects on global brain states. Our findings can be leveraged for developing personalized targeted treatments for neuropsychiatric disorders.
- 9 March 2026
- Published by IOP Publishing in Journal of Neural Engineering
- Vol. 23 (2) , 026006
Open AccessInsight into the impact of focal stimulation on large-scale network dynamics
Objective. Intrinsic functional brain activity forms a hierarchy, with local neural circuits integrated into large-scale networks. Determining how perturbations to a single brain region can rapidly propagate through this hierarchy and reconfigure global brain state dynamics is essential for decoding neural communication and advancing neuromodulation paradigms. Most prior studies have used perturbations to study trial-averaged responses, which miss moment-to-moment fluctuations, or focused on inter-regional connectivity, which characterizes brain activity as pairwise relationships rather than global states. How focal stimulation reshapes dynamics of global brain states remains unclear. Approach. We bridged this gap by combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) with microstate analysis, which captures global brain state dynamics with millisecond resolution. In 36 healthy participants, we examined how single-pulse TMS to the dorsolateral prefrontal cortex (DLPFC) and primary motor cortex (M1) reshapes the dynamics of the canonical EEG microstates (A–E) post-pulse. As key nodes of frontoparietal and primary motor networks, respectively, these targets let us investigate how stimulation of functionally distinct regions may differentially induce changes in global brain state dynamics. Analyses were conducted across repeated sessions within participants and validated in an independent dataset to ensure robustness and generalizability. Main results. Compared to pre-pulse baseline, DLPFC stimulation increased the occurrence and transitions of microstates D and E while suppressing those of A and B. These effects replicated across sessions and were validated in an independent dataset. Conversely, M1 stimulation increased microstate A occurrence post-pulse while reducing the occurrence of B. Furthermore, post-pulse microstate dynamics differed significantly from baseline after DLPFC stimulation compared to M1. Significance. These findings demonstrate that focal stimulation induces region-specific effects on global brain state dynamics, providing a mechanistic foundation for neuromodulation strategies to harness site-specific effects on global brain states. Our findings can be leveraged for developing personalized targeted treatments for neuropsychiatric disorders.
- Open Access
- 26 December 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (3) , 185-198
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l’étude CAN-BIND-1
Objectives: Current pharmacological antidepressant treatments suffer from low remission rates and slow initiation of therapeutic effects. In addition, the development of new antidepressant treatments is confounded by the lack of consensus on efficient and valid neurophysiological targets. Temporal complexity is an alternative measure of dynamic brain activity that estimates brain signal variability at several timescales. It can be easily extracted from non-invasive brain recordings and provides new insights into pathophysiological mechanisms. We aim to assess the potential of brain temporal complexity as a novel neuromarker to predict the effectiveness of antidepressant treatments. Method: We measured longitudinal changes in temporal complexity of electroencephalography signals in patients undergoing 8 weeks of escitalopram treatment through a Canadian Biomarker Integration Network in Depression (CAN-BIND) trial. Results: As early as 2 weeks after the start of treatment, reduction of complexity in fine timescales was associated with improvement in depressive symptoms. After 8 weeks of treatment, the treatment-related effect shifted towards an increase in coarse timescale complexity, linked to symptom improvement. Conclusions: These results suggest a relative shift away from local, segregated information processing, measured by complexity at fine timescales, in the short term, potentially in favour of a higher long-range communication across networks, as indicated by higher complexity measures at coarse timescales in the long term. Further research into the modulation of multiscale temporal complexity by antidepressant treatments could open new possibilities for faster-acting and more efficient treatments.
- 26 December 2025
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (3) , 185-198
Open AccessModulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l’étude CAN-BIND-1
Objectives: Current pharmacological antidepressant treatments suffer from low remission rates and slow initiation of therapeutic effects. In addition, the development of new antidepressant treatments is confounded by the lack of consensus on efficient and valid neurophysiological targets. Temporal complexity is an alternative measure of dynamic brain activity that estimates brain signal variability at several timescales. It can be easily extracted from non-invasive brain recordings and provides new insights into pathophysiological mechanisms. We aim to assess the potential of brain temporal complexity as a novel neuromarker to predict the effectiveness of antidepressant treatments. Method: We measured longitudinal changes in temporal complexity of electroencephalography signals in patients undergoing 8 weeks of escitalopram treatment through a Canadian Biomarker Integration Network in Depression (CAN-BIND) trial. Results: As early as 2 weeks after the start of treatment, reduction of complexity in fine timescales was associated with improvement in depressive symptoms. After 8 weeks of treatment, the treatment-related effect shifted towards an increase in coarse timescale complexity, linked to symptom improvement. Conclusions: These results suggest a relative shift away from local, segregated information processing, measured by complexity at fine timescales, in the short term, potentially in favour of a higher long-range communication across networks, as indicated by higher complexity measures at coarse timescales in the long term. Further research into the modulation of multiscale temporal complexity by antidepressant treatments could open new possibilities for faster-acting and more efficient treatments.
- Open Access
- 15 July 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 178, 2110932
Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in Depression
- 15 July 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 178, 2110932
Open AccessStandardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in Depression
- Open Access
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-11
BRieFLY: Mindful Breathing and Playful Interaction to Foster Self-Connection in Mixed Reality
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-11
Open AccessBRieFLY: Mindful Breathing and Playful Interaction to Foster Self-Connection in Mixed Reality
- Open Access
- 12 October 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-11
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study
Current pharmacological agents for depression have limited efficacy in achieving remission. Developing and validating new medications is challenging due to limited biological targets. This study aimed to link electrophysiological data and symptom improvement to better understand mechanisms underlying treatment response. Longitudinal changes in neural oscillations were assessed using resting-state electroencephalography (EEG) data from two Canadian Biomarker Integration Network in Depression studies, involving pharmacological and cognitive behavioral therapy (CBT) trials. Patients in the pharmacological trial received eight weeks of escitalopram, with treatment response defined as ≥ 50% decrease in Montgomery–Åsberg Depression Rating Scale (MADRS). Early (baseline to week 2) and late (baseline to week 8) changes in neural oscillation were investigated using relative power spectral measures. An association was found between an initial increase in theta and symptom improvement after 2 weeks. Additionally, late increases in delta and theta, along with a decrease in alpha, were linked to a reduction in MADRS after 8 weeks. These late changes were specifically observed in responders. To assess specificity, we extended our analysis to the independent CBT cohort. Responders exhibited an increase in delta and a decrease in alpha after 2 weeks. Furthermore, a late (baseline to week 16) decrease in alpha was associated with symptom improvement following CBT. Results suggest a common late decrease in alpha across both treatments, while modulatory effects in theta may be specific to escitalopram treatment. This study offers insights into electrophysiological markers indicating a favorable response to antidepressants, enhancing our comprehension of treatment response mechanisms in depression.
- 12 October 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-11
Open AccessModulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study
Current pharmacological agents for depression have limited efficacy in achieving remission. Developing and validating new medications is challenging due to limited biological targets. This study aimed to link electrophysiological data and symptom improvement to better understand mechanisms underlying treatment response. Longitudinal changes in neural oscillations were assessed using resting-state electroencephalography (EEG) data from two Canadian Biomarker Integration Network in Depression studies, involving pharmacological and cognitive behavioral therapy (CBT) trials. Patients in the pharmacological trial received eight weeks of escitalopram, with treatment response defined as ≥ 50% decrease in Montgomery–Åsberg Depression Rating Scale (MADRS). Early (baseline to week 2) and late (baseline to week 8) changes in neural oscillation were investigated using relative power spectral measures. An association was found between an initial increase in theta and symptom improvement after 2 weeks. Additionally, late increases in delta and theta, along with a decrease in alpha, were linked to a reduction in MADRS after 8 weeks. These late changes were specifically observed in responders. To assess specificity, we extended our analysis to the independent CBT cohort. Responders exhibited an increase in delta and a decrease in alpha after 2 weeks. Furthermore, a late (baseline to week 16) decrease in alpha was associated with symptom improvement following CBT. Results suggest a common late decrease in alpha across both treatments, while modulatory effects in theta may be specific to escitalopram treatment. This study offers insights into electrophysiological markers indicating a favorable response to antidepressants, enhancing our comprehension of treatment response mechanisms in depression.
- Open Access
- 20 August 2024
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 44 (39)
Influence of Large-Scale Brain State Dynamics on the Evoked Response to Brain Stimulation
Understanding how spontaneous brain activity influences the response to neurostimulation is crucial for the development of neurotherapeutics and brain–computer interfaces. Localized brain activity is suggested to influence the response to neurostimulation, but whether fast-fluctuating (i.e., tens of milliseconds) large-scale brain dynamics also have any such influence is unknown. By stimulating the prefrontal cortex using combined transcranial magnetic stimulation (TMS) and electroencephalography, we examined how dynamic global brain state patterns, as defined by microstates, influence the magnitude of the evoked brain response. TMS applied during what resembled the canonical Microstate C was found to induce a greater evoked response for up to 80 ms compared with other microstates. This effect was found in a repeated experimental session, was absent during sham stimulation, and was replicated in an independent dataset. Ultimately, ongoing and fast-fluctuating global brain states, as probed by microstates, may be associated with intrinsic fluctuations in connectivity and excitation–inhibition balance and influence the neurostimulation outcome. We suggest that the fast-fluctuating global brain states be considered when developing any related paradigms.
- 20 August 2024
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 44 (39)
Open AccessInfluence of Large-Scale Brain State Dynamics on the Evoked Response to Brain Stimulation
Understanding how spontaneous brain activity influences the response to neurostimulation is crucial for the development of neurotherapeutics and brain–computer interfaces. Localized brain activity is suggested to influence the response to neurostimulation, but whether fast-fluctuating (i.e., tens of milliseconds) large-scale brain dynamics also have any such influence is unknown. By stimulating the prefrontal cortex using combined transcranial magnetic stimulation (TMS) and electroencephalography, we examined how dynamic global brain state patterns, as defined by microstates, influence the magnitude of the evoked brain response. TMS applied during what resembled the canonical Microstate C was found to induce a greater evoked response for up to 80 ms compared with other microstates. This effect was found in a repeated experimental session, was absent during sham stimulation, and was replicated in an independent dataset. Ultimately, ongoing and fast-fluctuating global brain states, as probed by microstates, may be associated with intrinsic fluctuations in connectivity and excitation–inhibition balance and influence the neurostimulation outcome. We suggest that the fast-fluctuating global brain states be considered when developing any related paradigms.
- 22 December 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 95 (6) , 564-580
Transcranial Magnetic Stimulation–Electroencephalography for Biomarker Discovery in Psychiatry
- 22 December 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 95 (6) , 564-580
Transcranial Magnetic Stimulation–Electroencephalography for Biomarker Discovery in Psychiatry
- Open Access
- 4 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Baseline markers of cortical excitation and inhibition predict response to theta burst stimulation treatment for youth depression
Theta burst stimulation (TBS), a specific form of repetitive transcranial magnetic stimulation (TMS), is a promising treatment for youth with Major Depressive Disorder (MDD) who do not respond to conventional therapies. However, given the variable response to TBS, a greater understanding of how baseline features relate to clinical response is needed to identify which patients are most likely to benefit from this treatment. In the current study, we sought to determine if baseline neurophysiology, specifically cortical excitation and/or inhibition, is associated with antidepressant response to TBS. In two independent open-label clinical trials, youth (aged 16–24 years old) with MDD underwent bilateral dorsolateral prefrontal cortex (DLPFC) TBS treatment. Clinical trial one and two consisted of 10 and 20 daily sessions of bilateral DLPFC TBS, respectively. At baseline, single-pulse TMS combined with electroencephalography was used to assess the neurophysiology of 4 cortical sites: bilateral DLPFC and inferior parietal lobule. Measures of cortical excitation and inhibition were indexed by TMS-evoked potentials (i.e., P30, N45, P60, N100, and P200). Depression severity was measured before, during and after treatment completion using the Hamilton Rating Scale for Depression—17. In both clinical trials, the baseline left DLPFC N45 and P60, which are believed to reflect inhibitory and excitatory mechanisms respectively, were predictors of clinical response. Specifically, greater (i.e., more negative) N45 and smaller P60 baseline values were associated with greater treatment response to TBS. Accordingly, cortical excitation and inhibition circuitry of the left DLPFC may have value as a TBS treatment response biomarker for youth with MDD.Clinical trial 1 registration number: NCT02472470 (June 15, 2015).Clinical trial 2 registration number: NCT03708172 (October 17, 2018).
- 4 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Open AccessBaseline markers of cortical excitation and inhibition predict response to theta burst stimulation treatment for youth depression
Theta burst stimulation (TBS), a specific form of repetitive transcranial magnetic stimulation (TMS), is a promising treatment for youth with Major Depressive Disorder (MDD) who do not respond to conventional therapies. However, given the variable response to TBS, a greater understanding of how baseline features relate to clinical response is needed to identify which patients are most likely to benefit from this treatment. In the current study, we sought to determine if baseline neurophysiology, specifically cortical excitation and/or inhibition, is associated with antidepressant response to TBS. In two independent open-label clinical trials, youth (aged 16–24 years old) with MDD underwent bilateral dorsolateral prefrontal cortex (DLPFC) TBS treatment. Clinical trial one and two consisted of 10 and 20 daily sessions of bilateral DLPFC TBS, respectively. At baseline, single-pulse TMS combined with electroencephalography was used to assess the neurophysiology of 4 cortical sites: bilateral DLPFC and inferior parietal lobule. Measures of cortical excitation and inhibition were indexed by TMS-evoked potentials (i.e., P30, N45, P60, N100, and P200). Depression severity was measured before, during and after treatment completion using the Hamilton Rating Scale for Depression—17. In both clinical trials, the baseline left DLPFC N45 and P60, which are believed to reflect inhibitory and excitatory mechanisms respectively, were predictors of clinical response. Specifically, greater (i.e., more negative) N45 and smaller P60 baseline values were associated with greater treatment response to TBS. Accordingly, cortical excitation and inhibition circuitry of the left DLPFC may have value as a TBS treatment response biomarker for youth with MDD.Clinical trial 1 registration number: NCT02472470 (June 15, 2015).Clinical trial 2 registration number: NCT03708172 (October 17, 2018).
- 5 September 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (9) , e2336094
Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting more than 300 million people.1 Antidepressant medications are prescribed as a first-line treatment, but remission rates after the first and second trials range from 35% to 50%2,3 and decline further with subsequential trials.2 Given that each trial may take up to 12 weeks, predicting medication response could greatly reduce illness duration and associated negative outcomes.
- 5 September 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (9) , e2336094
Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting more than 300 million people.1 Antidepressant medications are prescribed as a first-line treatment, but remission rates after the first and second trials range from 35% to 50%2,3 and decline further with subsequential trials.2 Given that each trial may take up to 12 weeks, predicting medication response could greatly reduce illness duration and associated negative outcomes.
- Open Access
- 24 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
Cognitive behavioral therapy (CBT) is often recommended as a first-line treatment in depression. However, access to CBT remains limited, and up to 50% of patients do not benefit from this therapy. Identifying biomarkers that can predict which patients will respond to CBT may assist in designing optimal treatment allocation strategies. In a Canadian Biomarker Integration Network for Depression (CAN-BIND) study, forty-one adults with depression were recruited to undergo a 16-week course of CBT with thirty having resting-state electroencephalography (EEG) recorded at baseline and week 2 of therapy. Successful clinical response to CBT was defined as a 50% or greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to post-treatment completion. EEG relative power spectral measures were analyzed at baseline, week 2, and as early changes from baseline to week 2. At baseline, lower relative delta (0.5–4 Hz) power was observed in responders. This difference was predictive of successful clinical response to CBT. Furthermore, responders exhibited an early increase in relative delta power and a decrease in relative alpha (8–12 Hz) power compared to non-responders. These changes were also found to be good predictors of response to the therapy. These findings showed the potential utility of resting-state EEG in predicting CBT outcomes. They also further reinforce the promise of an EEG-based clinical decision-making tool to support treatment decisions for each patient.
- 24 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessResting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
Cognitive behavioral therapy (CBT) is often recommended as a first-line treatment in depression. However, access to CBT remains limited, and up to 50% of patients do not benefit from this therapy. Identifying biomarkers that can predict which patients will respond to CBT may assist in designing optimal treatment allocation strategies. In a Canadian Biomarker Integration Network for Depression (CAN-BIND) study, forty-one adults with depression were recruited to undergo a 16-week course of CBT with thirty having resting-state electroencephalography (EEG) recorded at baseline and week 2 of therapy. Successful clinical response to CBT was defined as a 50% or greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to post-treatment completion. EEG relative power spectral measures were analyzed at baseline, week 2, and as early changes from baseline to week 2. At baseline, lower relative delta (0.5–4 Hz) power was observed in responders. This difference was predictive of successful clinical response to CBT. Furthermore, responders exhibited an early increase in relative delta power and a decrease in relative alpha (8–12 Hz) power compared to non-responders. These changes were also found to be good predictors of response to the therapy. These findings showed the potential utility of resting-state EEG in predicting CBT outcomes. They also further reinforce the promise of an EEG-based clinical decision-making tool to support treatment decisions for each patient.